Other substances

Ruxolitinib

A Janus-associated kinase (JAK) inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

10
 Supporting references
0
 Contradictory references
51
 AI-suggested references
19
 Clinical trials

General information

Ruxolitinib is a Janus-associated kinase (JAK) inhibitor with immunomodulatory and potent antineoplastic activities (NCIt).

Ruxolitinib on DrugBank
Ruxolitinib on PubChem
Ruxolitinib on Wikipedia

Marketed as

JAKAVI; JAKAFI (RUXOLITINIB PHOSPHATE)

 

Structure image - Ruxolitinib

C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Supporting references

Link Tested on Impact factor Notes Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Severe severity Small molecule Cohort study 		Patients 8.67

Improvement in inflammatory cytokine profile, activated lymphocyte subsets and overall pulmonary function was observed. Sample size: 34. Dosage: Median 20 mg/day for median 13 days.

 Aug/19/2020
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
Small molecule Case series 		Patients 3.90

Rapid clinical improvement without serious adverse effects. Sample size: 18. Dosage: 20 mg twice daily on days 1-2; 10 mg twice daily deescalated to 5 mg twice daily on days 3-(max)14. Endpoints: Reduction of the degree of respiratory impairment (primary); restoration of the PaO2/FiO2 ratio and adverse effects (secondary). 

 Aug/04/2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
ARDS Small molecule Cohort study 		Patients 8.67

Rapid improvement in respiratory response and COVID-19-related inflammation in the majority of the patients. Sample size: 18. Dosage: 20 mg twice daily on days 1-2; de-escalation at 10 mg and then 5 mg twice daily on days 3-14(max).


 Sep/02/2020
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant)
Cancer Small molecule Case report 		"A patient with blastic plasmacytoid dendritic cell neoplasm" 2.97

Substantial improvement in respiratory function and overall clinical improvement in a leukemic patient non-responsive to tocilizumab treatment. Dosage: 20 mg twice daily on days 1 and 2; de-escalated on days 3 to 7.

 Sep/09/2020
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
Severe severity Small molecule Non-randomized controlled open trial 		Patients with pneumonia 8.67

Combined with steroid treatment, low-dose ruxolitinib administration was associated with lower mortality, significant decrease in CRP levels, and lower rate of unwanted outcomes. Sample size: 32 + 43 control. Dosage: 5 mg twice daily on days 1-7; once daily on days 8-10. Endpoints: Clinical recovery without mechanical ventilation, admission to ICU for mechanical ventilation and death (primary); a reduction of the inflammatory response (secondary).

 Nov/10/2020
COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib
Small molecule Case report 		Idiopatic pulmonary fibrosis patient 0.80

Rapid improvement in a patient with several comorbities (including idiopatic pulmonary fibrosis) and a long history of smoking.

 Nov/06/2020
Compassionate use of Ruxolitinib in patients with SarsCov‐2 infection not on mechanical ventilation. Short‐term effects on inflammation and ventilation
Small molecule Cohort study 		Patients 3.37

Significant decrecrease in CRP levels and increase in oxygenation (PaO2/FiO2). Sample size: 31. Dosage: 5 mg twice a day for 15 days.

 Jan/06/2021
JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells
Small molecule In vitro Mechanism 		Small Airway Epithelial Cells 6.27

The compound was shown to suppress interferon signalling-sensing enhancers in the ACE2 locus in vitro. This was hypothesized to contribute to its therapeutic effect in COVID-19 treatment. 

 Jun/02/2021
Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study
IL-1 Small molecule Critical severity Cohort study 		Critically ill COVID-19 patients 9.75

A combined treatment using anakinra and ruxolitinib led to clinical improvement and survival of 10 out of 11 critically ill patients. Sample size: 11. Dosage: 5 mg twice a day for 28 days. 

 Dec/14/2020

AI-suggested references

Link Publication date
Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
Dec/22/2021
Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting.
Mar/15/2022
The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice.
Dec/21/2021
In silico investigation of the interactions of certain drugs proposed for the treatment of Covid-19 with the paraoxonase-1.
Dec/13/2021
[Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT
Oct/05/2020
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.
Aug/08/2020
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Feb/17/2021
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Feb/04/2021
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Jan/12/2022
Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.
Oct/14/2020
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Apr/04/2022
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.
Aug/23/2021
JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Jul/29/2020
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
Oct/13/2020
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation
Sep/04/2021
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib
Mar/07/2021
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection
May/03/2021
"Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-gamma, IL-17A, and a Janus Kinase Inhibitor
Jun/26/2020
Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer
Sep/17/2021
Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine Storm
Jul/01/2020
Repurposing of gastric cancer drugs against COVID-19.
Sep/06/2021
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
May/08/2021
Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity
Nov/02/2020
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Jun/20/2020
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Jun/23/2020
Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib
Apr/22/2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.
Jun/25/2020
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Aug/12/2021
SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc
Aug/25/2020
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
Nov/25/2021
Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19
Aug/12/2020
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Jun/05/2020
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports
May/22/2020
Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids
Jun/10/2021
Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Jul/14/2020
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
Jul/08/2021
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.
Apr/22/2021
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
Feb/25/2021
JAK inhibitors and COVID-19
Jan/21/2021
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis
Dec/07/2021
Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation
Jan/31/2022
Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
Sep/30/2020
Inhibition of SARS-CoV-2 by type I and type III interferons
Feb/28/2022
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
Jun/27/2020
Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutieres Syndrome Treated With Ruxolitinib.
Apr/25/2022
Ruxolitinib in severe COVID-19 Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
Sep/19/2020
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
Jul/29/2021
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
May/26/2020
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Apr/26/2022
JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules.
Jul/30/2021
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
May/06/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04348071 Safety and Efficacy of Ruxolitinib for COVID-19 Withdrawn Phase 2|Phase 3 Jul/01/2021 Oct/01/2021
  • Alternative id - 20-0869
  • Interventions - Drug: Ruxolitinib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years to 89 Years   (Adult, Older Adult)
  • Outcome measures - Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)
NCT04348695 Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. Recruiting Phase 2 Apr/12/2020 May/13/2020
  • Alternative id - Ruxo-Sim-20|2020-001405-23
  • Interventions - Drug: Ruxolitinib plus simvastatin|Other: Standard of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario Madrid Sanchinarro, Madrid, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 94
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs
NCT04355793 Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection No longer available Jan/01/1970 Jan/01/1970
  • Alternative id - INCB 18424-MA-COVID-19-301
  • Interventions - Drug: Ruxolitinib
  • Study type - Expanded Access:Treatment IND/Protocol
  • Study results - No Results Available
  • Locations -
  • Study designs -
  • Enrollment -
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures -
NCT04337359 Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness No longer available Jan/01/1970 Jan/01/1970
  • Alternative id - CINC424A2001M
  • Interventions - Drug: Ruxolitinib
  • Study type - Expanded Access:Intermediate-size Population
  • Study results - No Results Available
  • Locations -
  • Study designs -
  • Enrollment -
  • Age - 6 Years to 90 Years   (Child, Adult, Older Adult)
  • Outcome measures -
NCT04359290 Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS Completed Phase 2 Jul/01/2020 Jul/30/2021
  • Alternative id - KKS-278
  • Interventions - Drug: Ruxolitinib administration
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Andreas Neubauer, Marburg, Germany
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 15
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Overall survival|Assessment of the duration of ventilation support|cytokine storm|time on ICU|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)|Rates of flow|Gas exchange|Forced expiratory volume in 1 second (FEV1)|Forced vital capacity (FVC)|Tiffeneau-Pinelli index
NCT04354714 Ruxolitinib to Combat COVID-19 Withdrawn Phase 2 Jun/30/2020 Dec/31/2021
  • Alternative id - 04-13-20-DiPersio
  • Interventions - Drug: Ruxolitinib|Procedure: Peripheral blood draw
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0|Proportion of participants with detectable virus
NCT04374149 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS Completed Phase 2 Apr/30/2020 Dec/01/2020
  • Alternative id - PHU COVID-19-001
  • Interventions - Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Prisma Health, Greenville, South Carolina, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 12 Years to 80 Years   (Child, Adult, Older Adult)
  • Outcome measures - C-reactive Protein (CRP) Levels at Baseline and Day 14|Cytokine Levels at Baseline and Day 14
NCT04334044 Treatment of SARS Caused by COVID-19 With Ruxolitinib Completed Phase 1|Phase 2 Sep/01/2020 Apr/30/2021
  • Alternative id - HAL 345/2020
  • Interventions - Drug: Ruxolitinib Oral Tablet
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 77
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate
NCT04338958 Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation Completed Phase 2 Apr/22/2020 Jul/15/2021
  • Alternative id - RuxCoFlam
  • Interventions - Drug: Ruxolitinib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SRH Wald-Klinikum Gera GmbH, Gera, Germany|University Hospital Jena, Jena, Germany|UKSH, Campus Lübeck, Lübeck, Germany|Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Germany
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 193
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - overall response rate in reversal of hyperinflammation
NCT04377620 Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) Terminated Phase 3 May/24/2020 Feb/26/2021
  • Alternative id - INCB 18424-369
  • Interventions - Drug: Placebo|Drug: Ruxolitinib
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Honor Health Research Institute, Scottsdale, Arizona, United States|Sharp Memorial Hospital, San Diego, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Teradan Clinical Trials, Brandon, Florida, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Northshore University Health System, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Healthpartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Njms Clinical Research Unit, Newark, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Kettering Cancer Care, Dayton, Ohio, United States|Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|Allegheny Health Network, Wexford, Pennsylvania, United States|St David'S Medical Center, Austin, Texas, United States|University of Texas Health Science Center At Houston - McGovern Medical School, Houston, Texas, United States|University of Texas Health Science Cente, San Antonio, Texas, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States|Sbih City Hospital 15, Saint Petersburg, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 211
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Percentage of Participants Who Have Died Due to Any Cause|Number of Ventilator Free Days|Number of ICU Free Days|Oxygen Free Days|Vasopressor Free Days|Hospital Free Days|Percentage of Participants With at Least 2-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With at Least 1-point Improvement in the COVID-19 Ordinal Scale|Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale|Percentage of Participants With the COVID-19 Ordinal Scale Reported|Change in the COVID-19 9-point Ordinal Scale|Change in SOFA Score|Number and Percentage of Participants With Treatment-related Side Effects and Serious Adverse Events
NCT04424056 A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease Not yet recruiting Phase 3 Sep/01/2020 Nov/01/2022
  • Alternative id - 2020-23
  • Interventions - Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Assistance Publique Hôpitaux de Marseille, Marseille, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 216
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Ventilation free days at D28
NCT04362137 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm Completed Phase 3 May/02/2020 Oct/17/2020
  • Alternative id - CINC424J12301|INCB 18424-368|2020-001662-11
  • Interventions - Drug: Ruxolitinib|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, C A B A, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Blumenau, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sorocaba, SP, Brazil|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Colombes Cedex, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 432
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care|Clinical Status|Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status|Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status|Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status|Time to Improvement in Clinical Status|Mean Change From Baseline in the Clinical Status|Mortality Rate|Proportion of Patients Requiring Mechanical Ventilation|Duration of Hospitalization|Time to Hospital Discharge or to a NEWS2 Score of ≤2|Change From Baseline in NEWS2 Score|Change From Baseline in SpO2/FiO2 Ratio|Proportion of Patients With no Oxygen Therapy
NCT04361903 Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection Not yet recruiting Apr/25/2020 May/31/2020
  • Alternative id - 2020.COVID-19.RUXO106
  • Interventions - Drug: Ruxolitinib Oral Tablet
  • Study type - Observational
  • Study results - No Results Available
  • Locations -
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 13
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19|Improvement of respiratory performance - Arterial Blood Gas Analisys - pH|Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2|Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2|Improvement of respiratory performance - ratio values|Evaluation of known adverse events related to the use of the drug - D-Dimer|Evaluation of known adverse events related to the use of the drug - fibrinogen|Evaluation of known adverse events related to the use of the drug - transaminases|Evaluation of known adverse events related to the use of the drug - aPTT|Evaluation of known adverse events related to the use of the drug - INR|Evaluation of known adverse events related to the use of the drug - glycemia|Evaluation of known adverse events related to the use of the drug - creatinine|Evaluation of known adverse events related to the use of the drug - Leucocytes count|Evaluation of known adverse events related to the use of the drug - Leucocytes formula|Evaluation of the epidemiological parameters: Chest CT|Evaluation of the epidemiological parameters: Eco Chest|Evaluation of the epidemiological parameters: CHEST X-ray|Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment|Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy
NCT04414098 Ruxolitinib in the Treatment of Covid-19 Not yet recruiting Phase 2 Jun/01/2020 Sep/15/2020
  • Alternative id - CZabala
  • Interventions - Drug: INC424 / Ruxolitinib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinib
NCT04477993 Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 Terminated Phase 2|Phase 3 Aug/14/2020 Mar/29/2021
  • Alternative id - 32894720.3.0000.0068
  • Interventions - Drug: Janus Kinase Inhibitor (ruxolitinib)|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital das Clínicas, Sao Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 5
  • Age - 18 Years to 95 Years   (Adult, Older Adult)
  • Outcome measures - A composite outcome of death or ICU admission or mechanical ventilation at day 14.|A composite outcome of death or ICU admission or mechanical ventilation at day 28|Time to treatment failure|Overall survival at days 14 and 28|Cumulative incidence of ICU admission rate at days 14 and 28|Cumulative incidence of mechanical ventilation at days 14 and 28|Duration of hospital stay|Duration of ICU stay|Duration of mechanical ventilation|Duration of non-invasive ventilation|Secondary hemophagocytic syndrome rate|Cumulative incidence nosocomial infection rate at days 14 and 28|Incidence of discontinuation of oxygen supplementation at days 14 and 28|Rate of grade 1-2 and 3-5 emerging adverse events at day 28|Cumulative dose of methylprednisolone at days 14 and 28|Change in PaO2/FiO2 ratio from baseline to days 14 and 28|Change in interleukin 6 levels [pg/mL] from baseline to days 14 and 28|Change in d-dimer levels [ng/mL] from baseline to days 14 and 28|Change in fibrinogen levels [mg/dL] from baseline to days 14 and 28|Change in ferritin levels [ng/mL] from baseline to days 14 and 28|Change in C reactive protein levels [mg/L] from baseline to days 14 and 28|Change in alanine aminotransferase [U/L] from baseline to days 14 and 28|Change in aspartate aminotransferase [U/L] from baseline to days 14 and 28|Change in creatinine levels [mg/dL] from baseline to days 14 and 28|Change in glucose levels [mg/dL] from baseline to days 14 and 28|Change in hemoglobin levels [g/dL] from baseline to days 14 and 28|Change in platelet count [x10ˆ3/mmˆ3] from baseline to days 14 and 28|Change in absolute neutrophil count [x10ˆ3/mmˆ3] from baseline to days 14 and 28|Change in absolute neutrophil count [/mmˆ3] from baseline to days 14 and 28|Change in absolute lymphocyte count [/mmˆ3] from baseline to days 14 and 28|Change in prothrombin time ratio from baseline to days 14 and 28|Change in partial thromboplastin time ratio from baseline to days 14 and 28|Change in bilirubin [mg/dl] from baseline to days 14 and 28|Change in lactate dehydrogenase [U/L] from baseline to days 14 and 28|Change in CPK-MB [ng/mL] from baseline to days 14 and 28|Change in troponin [ng/mL] from baseline to days 14 and 28|Change in von Willebrand factor antigen level (VWF:Ag) [%] from baseline to days 14 and 28|Change in von Willebrand factor activity (ristocetin cofactor) [%] from baseline to days 14 and 28|Change in ADAMTS-13 [%] from baseline to days 14 and 28|Change in von Willebrand multimeters from baseline to days 14 and 28|Change in plasminogen activator inhibitor-1 levels [ng/mL] from baseline to days 14 and 28|Change in E-selectin levels [ng/mL] from baseline to days 14 and 28|Change in P-selectin levels [ng/mL] from baseline to days 14 and 28|Change in endothelin [fmol/mL] from baseline to days 14 and 28|Change in circulating microparticles from baseline to days 14 and 28|Change in thromboelastography from baseline to days 14 and 28
NCT04581954 Inflammatory Signal Inhibitors for COVID-19 (MATIS) Recruiting Phase 1|Phase 2 Oct/02/2020 Dec/01/2021
  • Alternative id - 20HH5926|2020-001750-22
  • Interventions - Drug: Ruxolitinib|Drug: Fostamatinib|Other: Standard of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Imperial College Healthcare NHS Trust, London, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 456
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Number and proportion of patients requiring invasive ventilation|Number and proportion of patients requiring non-invasive ventilation (CPAP and high flow nasal oxygen)|Number and proportion of patients requiring invasive ventilation or extracorporeal membrane oxygenation (ECMO)|Number and proportion of patients requiring non-invasive ventilation including continuous positive airway pressure (CPAP) or high flow nasal oxygen|Number and proportion of patients requiring renal replacement therapy|Number and proportion of patients experiencing venous thromboembolism events|Length of stay|Number and proportion of serious adverse events and discontinuations|Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale
NCT04366232 Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation Terminated Phase 2 Aug/19/2020 Oct/02/2020
  • Alternative id - 2020-CHITS-003|2020-001963-10
  • Interventions - Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Biological criteria|Duration of oxygen therapy (days)|Number of intensive care units admissions|Number of days in intensive care units|Mortality rate|Total number of days in hospital|Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score)|Number of bacterial and/or fungal sepsis
NCT04331665 Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia Terminated Not Applicable May/21/2020 Mar/24/2021
  • Alternative id - U-DEPLOY: RUX-COVID|20-5315
  • Interventions - Drug: Ruxolitinib
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay
NCT04403243 COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Recruiting Phase 2 May/08/2020 Aug/23/2020
  • Alternative id - MSU080520
  • Interventions - Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 70
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline|Combine endpoint: Time to death or mechanical ventilation|C-reactive protein|D-dimer|EuroQol Group. EQ-5D™|exposure area on lung CT
Export (.csv)